1. Introduction {#s0005}
===============

Alopecia areata (AA) is a polygenic autoimmune disease that results in hair loss that ranges in presentation from circular patches on the scalp that can often undergo spontaneous resolution to complete hair loss that may persist for life. There are currently no FDA-approved treatments for AA, and treatment regimens for patients with severe disease are empiric and frequently unsatisfactory. Recent work in human subjects has identified several genes underlying AA ([@bb0005], [@bb0010]), as well as a prominent interferon (IFN) signature in the AA scalp ([@bb0015]), inviting trials targeting this pathway for treatment purposes.

Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome (OMIM [256040](256040){#ir0030}) is a monogenic autoinflammatory syndrome that was initially described in 2010 ([@bb0020]). Patients present within the first six months of life with recurrent episodes of fever, periocular erythema and edema, annular violaceous plaques (Supplementary Fig. 1) and lipodystrophy ([@bb0020], [@bb0025], [@bb0030]). Alopecia is not reported as a part of the CANDLE phenotype or other immunoproteasome-related disorders ([@bb0020], [@bb0035], [@bb0040]). Mutations have been discovered in *PSMB8*, whose gene product is a component of the immunoproteasome, in some, but not all patients, with CANDLE syndrome ([@bb0030]). There are currently no well-established treatments for this rare orphan disease. Whole genome expression analysis of peripheral blood mononuclear cells identified the IFN pathway as being highly dysregulated in these patients ([@bb0030]), establishing a possible target for the development of new treatments.

AA and CANDLE syndrome are both characterized by prominent IFN signatures, albeit as a result of different genetic mechanisms. Type I and type II IFNs signal through cell surface receptors that initially activate JAK kinases, specifically JAK1 and either TYK2 or JAK2, respectively. Small molecule JAK inhibitors have been developed and are currently available for myelofibrosis ([@bb0045]) and rheumatoid arthritis (RA) ([@bb0050]). This class of drugs offers the convenience of being orally bioavailable when compared with biologic inhibitors of IFNs, which require parenteral administration. Here, we describe a patient enrolled in a clinical trial of baricitinib, an oral JAK inhibitor with relative selectivity for JAK1 and JAK2, for CANDLE syndrome who experienced dramatic resolution of his AA.

A 17-year-old man with chronic long-standing AA was enrolled in a clinical trial examining the efficacy of baricitinib for a proposed IFN mediated autoinflammatory syndrome, CANDLE syndrome ([NCT01724580](ctgov:NCT01724580){#ir0035}). The diagnosis of CANDLE syndrome was based on the typical clinical features of widespread annular violaceous skin lesions and the multisystemic inflammatory characteristics ([@bb0025]) and had been confirmed by finding a homozygous mutation in *PSMB8* ([@bb0030]). Prior to the trial, he had been treated for CANDLE syndrome with two courses of intravenous pulses of methylprednisolone and oral methotrexate (10 mg/week). At the time of study initiation, he had been taking oral prednisone at a dose of 12 mg/day.

The patient suffered from a chronic patch-type AA for seven years, which involved mainly his occipital scalp. He had been treated with dithranol cream and minoxidil in the past without improvement of his alopecia. In the time preceding his enrollment in the trial, the patient experienced progression of his disease to an ophiasis pattern, a form of AA that is usually recalcitrant to treatment ([@bb0055]), despite being on an immunosuppressive regimen for CANDLE syndrome.

2. Methods {#s0010}
==========

2.1. Clinical Studies {#s0015}
---------------------

Due to the observation that increased STAT-1 phosphorylation and a strong IFN response signature are observed in CANDLE patients ([@bb0030]), a treatment trial with the JAK 1/2 inhibitor baricitinib was initiated at the National Institutes of Health ([NCT01724580](ctgov:NCT01724580){#ir0040}). The patient was enrolled in this study and started to receive once-daily oral baricitinib in September 2012, initially at a dose of 7 mg daily and 6 months later at 7 mg in the morning and 4 mg in the evening, with gradual tapering of oral corticosteroids to 3 mg daily. Informed consent was provided by the patient and his guardians. All forms and protocol were approved by the NIDDK/NIAMS IRB, and the study number on clinicaltrials.gov is [NCT01724580](ctgov:NCT01724580){#ir0045}.

2.2. Animal Studies {#s0020}
-------------------

We performed three sets of *in vivo* experiments to determine the mechanistic basis for treatment response of AA with baricitinib. Baricitinib was obtained from MedKoo Biosciences (Chapel Hill, NC). The C3H/HeJ graft-recipient mouse model of AA was used for these experiments. C3H/HeJ mice spontaneously develop alopecia at a rate of 10--20% by 6--18 months of age. C3H/HeJ mice that receive skin grafts of alopecic skin from donor alopecic C3H/HeJ mice develop the disease 95--100% of the time by 10 weeks post-transplant. Using the C3H/HeJ grafted mouse model of AA, we first conducted experiments to prevent onset of disease by administering baricitinib at the time of grafting. Briefly, alopecic skin from a C3H/HeJ mouse that spontaneously developed hair loss was grafted onto 8--10 week old C3H/HeJ mice free of disease. At the time of grafting, an osmotic pump (Alzet) that administered approximately 0.7 mg/day of baricitinib or placebo was implanted. Osmotic pumps were changed monthly.

A time-to-event survival analysis for interval censored data was performed. The survival and interval packages in R were used to perform log-rank tests. The hypothesis that the survival distributions are equal in the (n = 10) baricitinib-treated mice and (n = 10) placebo-treated mice is rejected at the 5% level using Sun\'s score to perform an exact log-rank two-sample test with the p-value of 0.0035.

We then conducted treatment experiments in the setting of established AA in mice, using both systemic delivery and topical delivery of baricitinib. C3H/HeJ recipients of alopecic C3H/HeJ mouse skin were aged at least an additional 12 weeks to allow for near complete alopecia prior to either implantation of osmotic pumps or topical treatment. Osmotic pump administration was conducted in a similar manner as for the prevention experiments. For topical treatment experiments, vehicle control or 0.5% baricitinib was applied topically daily. For these experiments, the R package nparLD was used to test the hypothesis that there exists a treatment by time interaction. A F1--LD--F1 design was employed. The hypothesis of no interaction, *i.e.*, parallel time profiles, is rejected at the 5% level using both the Wald-type statistic and the ANOVA-type statistic with the p-values of 5.80 × 10^− 22^ and 3.74 × 10^− 15^, respectively, for the baricitinib-treated (n = 8) and placebo-treated (n = 8) groups.

At the indicated time points, skin samples were taken for the purposes of immunohistochemical staining and microscopy, immune infiltrate extraction and flow cytometric analysis, and/or RNA expression studies (see Supplementary Materials and methods). Microarray data were deposited in Gene Expression Omnibus with accession number [GSE61555](ncbi-geo:GSE61555){#ir0050}.

3. Results {#s0025}
==========

3.1. Clinical Response to Baricitinib {#s0030}
-------------------------------------

Soon after starting baricitinib treatment, there was a remarkable improvement in the patient\'s AA, regressing to only a single patch of hair loss on his occipital scalp three months after starting baricitinib treatment ([Fig. 1](#f0005){ref-type="fig"}). There was a steady regrowth of hair on this single patch, until he had complete resolution of hair loss nine months after starting treatment ([Fig. 1](#f0005){ref-type="fig"}). With continued baricitinib treatment, his hair regrowth persisted. Today, under baricitinib treatment, the patient has complete hair growth on his scalp, with no signs of recurrence of AA.

3.2. Resolution of the IFN Signature {#s0035}
------------------------------------

Intrigued by the rapid improvement in his AA, we evaluated the effect of baricitinib in a mouse model of AA and conducted mechanistic studies to understand the action of baricitinib. We conducted three sets of *in vivo* experiments to investigate the mechanisms of action of baricitinib for AA. C3H/HeJ grafted alopecic mice were treated with systemically administered baricitinib or vehicle/placebo control either prior to (Supplementary Fig. 2) or following the establishment of alopecia (Supplementary Fig. 3). Furthermore, C3H/HeJ grafted alopecic mice were treated with a topical formulation of baricitinib or vehicle control after the mice developed alopecia ([Fig. 2](#f0010){ref-type="fig"}). In all three cases, hair growth was consistently observed in baricitinib-treated mice, compared with no clinical evidence of hair regrowth in vehicle control treated mice ([Fig. 2](#f0010){ref-type="fig"} and Supplementary Figs. 2 and 3). Skin biopsies were taken 12 weeks after the start of treatment and assessed for immune cell infiltration and loss of immune privilege. Baricitinib treated mice exhibited substantially reduced inflammation as assessed by H&E staining, reduced CD8 infiltration, and reduced MHC class I and class II expression when compared with vehicle-control treated mice ([Fig. 2](#f0010){ref-type="fig"}). CD8^+^NKG2D^+^ cells, critical effectors of disease in murine and human AA, were greatly diminished in baricitinib treated mice compared with vehicle control treated mice ([Fig. 2](#f0010){ref-type="fig"}).

To define the molecular response to baricitinib, we performed gene expression profiling of treated skin in both the prevention and treatment models. Our previous studies defined an Alopecia Areata Disease Activity Index (ALADIN) biomarker for response to treatment ([@bb0015]), which monitors three distinct gene expression signatures, one of which is the IFN response. In all three contexts, we observed rapid normalization of the IFN gene expression signature in response to baricitinib ([Fig. 3](#f0015){ref-type="fig"} and Supplementary Figs. 2 and 3). Both the IFN and cytotoxic T lymphocyte (CTL) components of the ALADIN strongly discriminated between effectively treated mice and mice that did not exhibit disease resolution.

4. Discussion {#s0040}
=============

In this study, we report a dramatic clinical response to the JAK inhibitor baricitinib in a patient with longstanding AA. We further define the mechanism of response to baricitinib and resolution of the IFN gene expression signature in the AA mouse model. Recently, three independent studies reported similar clinical responses to JAK inhibitors in patients with AA. We recently showed that the JAK inhibitor ruxolitinib, which also has relative selectivity for JAK1 and JAK2 and is currently approved for myelofibrosis, reversed disease in three AA patients in an open-label clinical trial of oral drug in moderate-to-severe disease ([@bb0015]). Secondly, a single patient with alopecia universalis and psoriasis was treated orally with tofacitinib, an FDA approved JAK inhibitor with higher affinity to JAK3, and also showed a clinical response ([@bb0060]). Lastly, a patient with essential thrombocythemia and alopecia universalis was treated with ruxolitinib and exhibited striking and near-complete hair regrowth after 10 months of treatment ([@bb0065]). Our previous studies using both ruxolitinib and tofacitinib in the C3H/HeJ mouse model of AA demonstrated the molecular underpinnings of the response and resolution of the disease at the cellular and molecular levels ([@bb0015]).

Small molecule JAK inhibitors offer several advantages when compared with a therapeutic strategy centered on targeting cytokines with biologics. First, small molecule JAK inhibitors have oral bioavailability, making them more attractive to patients and likely increasing adherence. Second, JAK inhibitors inhibit multiple pathogenic pathways simultaneously, including both type I and type II IFN receptor pathways, both of which appear to be active in AA ([@bb0015], [@bb0070], [@bb0075]). Notably, small molecule JAK inhibitors may be developed into a topical form in the future, with two published studies examining the efficacy of a topical JAK inhibitor for the treatment of psoriasis ([@bb0080], [@bb0085]). A topical JAK inhibitor may decrease the risk/benefit profile of this class of drugs. Clinical trials examining the efficacy of baricitinib in the context of the compassionate use protocol for CANDLE syndrome as well as for RA are currently underway. Results from a phase IIb clinical trial for baricitinib in RA have been released showing a statistically significant improvement in ACR20 between baricitinib treatment and placebo ([@bb0090]), and phase III trials are currently underway for this indication. AA may represent another potential indication for which baricitinib may be tested in the future. Taken together, the recent reports of dramatic responses to treatment using JAK inhibitors invite broader clinical exploration of the utility of these agents in AA.
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![Clinical response to baricitinib in CANDLE patient with AA.\
Scalp photos of the CANDLE patient with AA prior to and during treatment with baricitinib. Timeline showing the approximate dates that photographs were taken and period in which the patient was being treated with baricitinib.](gr1){#f0005}

![Treatment of AA in C3H/HeJ mouse model.\
C3H/HeJ graft recipient mice were treated with topical baricitinib or vehicle control after disease establishment. A, Photographs were taken at 12 weeks post-treatment. B, Graph of hair regrowth index in each group over time. C, Skin sections were taken at baseline and at 12 weeks post-treatment and stained with H&E or with antibodies to CD8, MHC class I, MHC class II, or ICAM-1. D, Frequency of CD8^+^NKG2D^+^ cells in treated skin.](gr2){#f0010}

![Normalization of IFN signature in baricitinib treated skin.\
A, Expression of indicated genes in skin and, B, ALADIN score plots, from C3H/HeJ grafted mice treated with topical baricitinib or vehicle control administered after the establishment of disease demonstrating resolution of IFN and CTL scores with baricitinib treatment only. Yellow, control treatment at week 0; orange, control treatment at week 12; red, baricitinib treatment at week 0; purple, baricitinib treatment at week 12.](gr3){#f0015}
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